Press release
Epidermolysis Bullosa Emerging and Marketed Drugs Assessment (2023 Updates) | Clinical and Non-Clinical Trials Evaluation, Latest FDA, EMA, and PMDA Approvals, Treatment Outlook, Competitive Landscape, and Key Companies
The Epidermolysis Bullosa Therapeutics dynamics are anticipated to evolve immensely in the coming years, owing to the increased patient pool and the expected entry of emerging therapies in the market. Some of the key companies in the Epidermolysis Bullosa therapeutics market include Amryt Pharma, Abeona Therapeutics, Castle Creek Pharmaceuticals, RegeneRx, Krystal Biotech, Fibrocell Technologies/Castle Creek Pharmaceuticals, RHEACELL GmbH, StemRim/Shionogi, Phoenix Tissue Repair (BridgeBio Pharma, Inc), Menlo Therapeutics, JCR Pharmaceutical, Amicus Therapeutics, and others.
"Epidermolysis Bullosa Pipeline Insight, 2023" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Epidermolysis Bullosa Therapeutics Market.
The report provides a detailed description of the drug, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any).
The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.
Epidermolysis Bullosa Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the key companies that are developing therapies in the Epidermolysis Bullosa Market.
• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Epidermolysis Bullosa treatment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Epidermolysis Bullosa market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Learn More about the Clinical and Commercial Development Activities in the Epidermolysis Bullosa Therapeutics Domain:
https://www.delveinsight.com/sample-request/epidermolysis-bullosa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
The Report Covers the Emerging Pipeline Products Under Different Phases of Clinical Development Like -
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
Route of Administration
Epidermolysis bullosa pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
Molecule Type
Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
Mechanism of Action of the Emerging Pipeline Therapies
• Collagen type VII replacements
• Gene transference
• Proto-oncogene protein c-bcl-2 modulators
• Angiogenesis inducing agents
• Ribosomal RNA modulators
Request for Sample PDF to Understand More About the Treatment Outlook and Future Perspectives:
https://www.delveinsight.com/sample-request/epidermolysis-bullosa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Major Clinical Developments in the Epidermolysis Bullosa Therapeutics Market
• On March 27, 2023, BPGbio Inc (BPG) announced that the company has reached a partnership agreement with Dystrophic Epidermolysis Bullosa Research Association of America (debra of America) for BPGbio's BPM 31510 for Epidermolysis Bullosa Phase II/III trial, which is anticipated to launch in the second half of the year. Through the partnership, debra of America will provide support to awareness, understanding, and key information towards patient recruitment and advocacy for the clinical trial.
• On February 14, 2023, RELIEF THERAPEUTICS Holding SA (SIX:RLF) (OTCQB:RLFTF) (ORCQB:RLFTY) ("Relief Therapeutics" or the "Company"), a biopharmaceutical company developing and commercializing novel, patent-protected products in select specialty and rare diseases, announced today the first three patients have been enrolled in a proof-of-concept, investigator-initiated study to evaluate RLF-TD011 as a treatment for epidermolysis bullosa (EB).
Epidermolysis Bullosa Therapeutics Analysis
Several major pharma and biotech companies are developing the therapies for Epidermolysis bullosa. Currently, Abeona Therapeutics is leading the therapeutics market with its Epidermolysis bullosa drug candidates in the most advanced stage of clinical development.
The Leading Companies in the Epidermolysis Bullosa Therapeutics Market Include:
• Abeona Therapeutics
• Aegle Therapeutics
• Amicus Therapeutics
• Amryt Pharma
• Castle Creek Biosciences
• Constant Therapeutics
• Fibrocell Technologies/Castle Creek Pharmaceuticals
• Holostem Terapie Avanzate
• InMed Pharmaceuticals Inc.
• Ishin Pharmaceutical
• JCR Pharmaceuticals
• Kangstem Biotech
• Krystal Biotech, Inc.
• Lenus Therapeutics, LLC
• Menlo Therapeutics
• Onconova Therapeutics, Inc.
• Phoenix Tissue Repair (BridgeBio Pharma, Inc)
• ProQR Therapeutics
• RegeneRx
• RHEACELL GmbH
• StemRim/Shionogi
• Wings Therapeutics Inc.
And Many Others
Epidermolysis Bullosa Emerging and Marketed Drugs Covered in the Report Include:
• AP-101: Amryt Pharma
• CCP-020: Castle Creek Pharmaceuticals
• D-Fi (FCX-007): Castle Creek Biosciences
• EB 101: Abeona Therapeutics
• FCX-007: Fibrocell Technologies
• KB103: Krystal Biotech
• PTR-01: Phoenix Tissue Repair
• Research program: ribosomal modulators: Zikani Therapeutics
• RGN-137: RegeneRx
• Ubidecarenone: Berg Pharma
And Many More
Get an in-depth Assessment of the Emerging Therapies and Key Companies:
https://www.delveinsight.com/sample-request/epidermolysis-bullosa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Table of Content
1. Report Introduction
2. Executive Summary
3. Epidermolysis Bullosa Current Treatment Patterns
4. Epidermolysis Bullosa - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Epidermolysis Bullosa Late-Stage Products (Phase-III)
7. Epidermolysis Bullosa Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Epidermolysis Bullosa Discontinued Products
13. Epidermolysis Bullosa Product Profiles
14. Epidermolysis Bullosa Key Companies
15. Epidermolysis Bullosa Key Products
16. Dormant and Discontinued Products
17. Epidermolysis Bullosa Unmet Needs
18. Epidermolysis Bullosa Future Perspectives
19. Epidermolysis Bullosa Analyst Review
20. Appendix
21. Report Methodology
Get Detailed Insights About the Reports Offerings:
https://www.delveinsight.com/sample-request/epidermolysis-bullosa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com
428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Epidermolysis Bullosa Emerging and Marketed Drugs Assessment (2023 Updates) | Clinical and Non-Clinical Trials Evaluation, Latest FDA, EMA, and PMDA Approvals, Treatment Outlook, Competitive Landscape, and Key Companies here
News-ID: 2991033 • Views: …
More Releases from DelveInsight Business Research LLP
Myelofibrosis Pipeline Report 2025 by DelveInsight: Key Insights into Clinical S …
DelveInsight's "Myelofibrosis Pipeline Insight" report provides comprehensive insights about 35+ companies and 40+ pipeline drugs in the Myelofibrosis pipeline landscape. It covers the Myelofibrosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Myelofibrosis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Stay ahead with the latest insights! Download DelveInsight's comprehensive Myelofibrosis…
Hemophilia Pipeline Landscape Report 2025: DelveInsight's Exclusive Report on Cu …
DelveInsight's "Hemophilia Pipeline Insight" report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in the Hemophilia pipeline landscape. It covers the Hemophilia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hemophilia therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Stay ahead with the latest insights! Download DelveInsight's comprehensive Hemophilia…
DelveInsight's NMIBC Pipeline 2025: Unveiling Drug Development Progress, Clinica …
DelveInsight's, "Non Muscle Invasive Bladder Cancer Pipeline Insight" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Non Muscle Invasive Bladder Cancer pipeline landscape. It covers the Non Muscle Invasive Bladder Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Non Muscle Invasive Bladder Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive…
Hearing Loss Pipeline 2025 by DelveInsight: Exploring Novel Mechanisms of Action …
DelveInsight's "Hearing Loss Pipeline Insight" report provides comprehensive insights about 32+ companies and 35+ pipeline drugs in Hthe earing Loss pipeline landscape. It covers the Hearing Loss pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hearing Loss therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Stay ahead with the latest insights!…
More Releases for Epidermolysis
Epidermolysis Bullosa Market to Reach USD 6.8 Billion by 2034
Epidermolysis bullosa (EB) is a group of rare, genetic skin disorders characterized by fragile skin that blisters and tears easily. Often referred to as "the butterfly skin disease," EB significantly impacts patients' quality of life and requires long-term supportive care. Historically, treatments were limited to wound management and pain control, but recent advancements in gene therapy, cell-based therapies, and biologics are opening new possibilities for disease-modifying interventions.
Download Full PDF Sample…
Epidermolysis Bullosa Pipeline Therapeutics Assessment Report 2024 (Updated)
DelveInsight's, "Epidermolysis Bullosa Pipeline Insight 2024" report provides comprehensive insights about 20+ companies and 21+ pipeline drugs in Epidermolysis Bullosa pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Epidermolysis Bullosa Research. Learn more about…
Epidermolysis Bullosa Pipeline, Clinical Trials Assessment, and FDA Approvals 20 …
DelveInsight's, "Epidermolysis Bullosa Pipeline Insight 2023" report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in the Epidermolysis Bullosa pipeline landscape. It covers the Epidermolysis Bullosa pipeline drug profiles, including Epidermolysis Bullosa clinical trials and nonclinical stage products. It also covers the Epidermolysis Bullosa therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways…
Epidermolysis Bullosa Market to Reach US$ 3,856.2 Million by 2033
Market Overview:
The 7 major epidermolysis bullosa markets reached a value of US$ 2,496.5 Million in 2022. Looking forward, IMARC Group expects the 7MM to reach US$ 3,856.2 Million by 2033, exhibiting a growth rate (CAGR) of 4% during 2023-2033.
The report offers a comprehensive analysis of the epidermolysis bullosa market in the United States, EU5 (including Germany, Spain, Italy, France, and the United Kingdom), and Japan. It covers aspects such as…
Singapore Dystrophic Epidermolysis Bullosa Treatment Market to Observe Strong De …
Dystrophic Epidermolysis Bullosa Treatment Market: Introduction
According to the report, the global dystrophic epidermolysis bullosa treatment market was valued over US$ 412 Mn in 2019 and is projected to expand at a CAGR of ~5% from 2020 to 2030. Dystrophic epidermolysis bullosa (DEB) is the second most common form of epidermolysis bullosa. The prevalence of DEB varies from 1 per 49,000 inhabitants in Scotland to 1 per 420,168 in the U.S. According to the U.S. National Library of Medicine,…
Epidermolysis Bullosa Market Insights, Share, Size, Companies, and Forecast 2032
DelveInsight's Epidermolysis Bullosa Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Epidermolysis Bullosa Market Size and Share in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
The Epidermolysis Bullosa Market report covers emerging drugs, current treatment practices, market share of individual therapies, and the current forecasted market size…
